French Recommendations on Strategies for Preventing and Treating Osteoporosis Induced by Adjuvant Breast Cancer Therapies.

[1]  E. Lespessailles,et al.  Vitamin D Supplementation in France in patients with or at risk for osteoporosis: Recent data and new practices. , 2020, Joint, bone, spine : revue du rhumatisme.

[2]  E. Lespessailles,et al.  2018 update of French recommendations on the management of postmenopausal osteoporosis. , 2018, Joint, bone, spine : revue du rhumatisme.

[3]  E. Rutgers,et al.  Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials , 2015, The Lancet.

[4]  J. Forbes,et al.  Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials , 2015, The Lancet.

[5]  E. Perez,et al.  5‐year follow‐up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial , 2015, Cancer.

[6]  R. Greil,et al.  Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[7]  S. Greenspan,et al.  Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial , 2015, Osteoporosis International.

[8]  J. Cuzick,et al.  Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. , 2014, The Lancet. Oncology.

[9]  Lara E Sucheston-Campbell,et al.  Bone Health History in Breast Cancer Patients on Aromatase Inhibitors , 2014, PloS one.

[10]  I. Smith,et al.  Status of adjuvant endocrine therapy for breast cancer , 2014, Breast Cancer Research.

[11]  M. Baier,et al.  Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study , 2014, Osteoporosis International.

[12]  C. Blomqvist,et al.  The effect of ovarian dysfunction on bone mineral density in breast cancer patients 10 years after adjuvant chemotherapy , 2014, Acta oncologica.

[13]  P. Sambrook,et al.  Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN Trial , 2013, Journal of Bone Oncology.

[14]  Karen A Gelmon,et al.  Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Park,et al.  Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study. , 2013, Endocrine journal.

[16]  J. Forbes,et al.  Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. , 2013 .

[17]  M. Gnant,et al.  Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? , 2012, Cancer treatment reviews.

[18]  D. Dodwell,et al.  Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial , 2012, Journal of bone oncology.

[19]  D. Chappard,et al.  High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy. , 2012 .

[20]  G. Tomlinson,et al.  Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. , 2012, The Lancet. Oncology.

[21]  E. Perez,et al.  Final 5‐year results of Z‐FAST trial , 2012, Cancer.

[22]  T. Ishikawa,et al.  Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results , 2012, Breast Cancer Research and Treatment.

[23]  P. Neven,et al.  Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial. , 2012, Clinical breast cancer.

[24]  A. Díez-Pérez,et al.  Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer. , 2012, Breast.

[25]  R. Rizzoli,et al.  Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper , 2012, Osteoporosis International.

[26]  Seung Ah Lee,et al.  Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients , 2011, Breast Cancer Research and Treatment.

[27]  A. Schneeweiss,et al.  Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study , 2011, Breast Cancer Research.

[28]  J. Nortier,et al.  The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies , 2011, Journal of Cancer Research and Clinical Oncology.

[29]  M. Beckmann,et al.  Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  Y. Ohashi,et al.  Effects of Exemestane, Anastrozole and Tamoxifen on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Early Breast Cancer Patients: Results of N-SAS BC 04, the TEAM Japan Substudy , 2011, Oncology.

[31]  E. Winer,et al.  Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. , 2011, European journal of cancer.

[32]  P. Neven,et al.  Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  S. Cawthorn,et al.  Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study , 2010, Breast Cancer Research and Treatment.

[34]  D. Cameron,et al.  Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency? , 2010, Breast Cancer Research and Treatment.

[35]  U. Dafni,et al.  Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial , 2010, Breast Cancer Research.

[36]  J. Mackey,et al.  Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  I. Chirivella,et al.  Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens , 2010, Breast Cancer Research and Treatment.

[38]  U. Albert,et al.  The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer. , 2009, European journal of cancer.

[39]  J. Forbes,et al.  Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  P. Goodwin,et al.  Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  A. Hasenburg,et al.  Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  A. Hasenburg,et al.  The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. , 2009, Breast.

[43]  R. Chlebowski,et al.  Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study , 2009, Breast Cancer Research and Treatment.

[44]  Muhammad Salim,et al.  Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  E. Perez,et al.  Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC , 2009, Breast Cancer Research and Treatment.

[46]  J. Eisman,et al.  Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. , 2009, JAMA.

[47]  F. Holmes,et al.  The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer. , 2008, Clinical breast cancer.

[48]  L. Lix,et al.  Tamoxifen use and osteoporotic fracture risk: a population-based analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  R. Chlebowski,et al.  Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  S. Cremers,et al.  Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  C. Blomqvist,et al.  Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  R. Greil,et al.  Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. , 2008, The Lancet. Oncology.

[53]  M. Aapro,et al.  Practical guidance for the management of aromatase inhibitor-associated bone loss. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  P. Vestergaard,et al.  Effect of Tamoxifen and Aromatase Inhibitors on the Risk of Fractures in Women with Breast Cancer , 2008, Calcified Tissue International.

[55]  J. Costantino,et al.  Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  P. Neven,et al.  Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole , 2008, Cancer.

[57]  M. Beckmann,et al.  Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  O. Johnell,et al.  FRAX™ and the assessment of fracture probability in men and women from the UK , 2008, Osteoporosis International.

[59]  R. Greil,et al.  Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. , 2007, Journal of the National Cancer Institute.

[60]  R. Eastell,et al.  Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. , 2007, European journal of cancer.

[61]  P. Delmas,et al.  Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. , 2007, Bone.

[62]  S. Cummings,et al.  Risk factors for breast cancer in older women: the relative contribution of bone mineral density and other established risk factors , 2007, Breast Cancer Research and Treatment.

[63]  E. Perez,et al.  Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  M. Gnant,et al.  Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  S. Cawthorn,et al.  Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. , 2007, The Lancet. Oncology.

[66]  S. Swain,et al.  Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  P. Lønning,et al.  Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. , 2006, European journal of cancer.

[68]  J. Cuzick,et al.  Effect of an Aromatase Inhibitor on BMD and Bone Turnover Markers: 2‐Year Results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230) , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[69]  Rashmi Kumar,et al.  NCCN Task Force Report: Bone Health in Cancer Care. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[70]  C. Blomqvist,et al.  Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  C. Hudis,et al.  Incidence of chemotherapy‐induced, long‐term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane , 2005, Cancer.

[72]  Robert B Livingston,et al.  Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. , 2005, Journal of the National Cancer Institute.

[73]  Michael Gnant,et al.  Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial , 2005, The Lancet.

[74]  Chiara Benedetto,et al.  Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  P. Lønning,et al.  Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  A. Shamseddine,et al.  Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. , 2005, The Journal of clinical endocrinology and metabolism.

[77]  A. M. López,et al.  Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. , 2005, Archives of internal medicine.

[78]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[79]  L. Rutqvist,et al.  Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  C. Blomqvist,et al.  Short-Term Intermittent Intravenous Clodronate in the Prevention of Bone Loss Related to Chemotherapy-Induced Ovarian Failure , 2004, Breast Cancer Research and Treatment.

[81]  S. Waldman,et al.  The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. , 2004, Bone.

[82]  W. Sauerbrei,et al.  Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) , 2003, Osteoporosis International.

[83]  C. Baudoin,et al.  Bone Mass Density and Risk of Breast Cancer and Survival in Older Women , 2003, European Journal of Epidemiology.

[84]  A. Hofman,et al.  Bone mineral density and the risk of breast cancer: the Rotterdam Study. , 2003, Bone.

[85]  C. Blomqvist,et al.  Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. , 2001, European journal of cancer.

[86]  J. Manola,et al.  Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  S. Cummings,et al.  Bone mass and breast cancer risk in older women: differences by stage at diagnosis. , 2001, Journal of the National Cancer Institute.

[88]  C. Blomqvist,et al.  The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer , 2001, British Journal of Cancer.

[89]  A. LaCroix,et al.  Bone mineral density and breast cancer risk in postmenopausal women. , 2001, Journal of clinical epidemiology.

[90]  J. Peng,et al.  Is there a reduced risk of breast cancer among women with hip fractures? , 1999, European Journal of Epidemiology.

[91]  T. Spector,et al.  A high incidence of vertebral fracture in women with breast cancer , 1999, British Journal of Cancer.

[92]  T. Powles,et al.  Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. , 1998, Journal of the National Cancer Institute.

[93]  J. Forbes,et al.  Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  C. Blomqvist,et al.  Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  P. Delmas,et al.  Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  S. Cummings,et al.  Bone Mineral Density and Risk of Breast Cancer in Older Women: The Study of Osteoporotic Fractures , 1996 .

[97]  P. Kelly,et al.  Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. , 1993, Bone and mineral.

[98]  H. Olsson,et al.  Reduced cancer morbidity and mortality in a prospective cohort of women with distal forearm fractures. , 1992, American journal of epidemiology.

[99]  R B Mazess,et al.  Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.

[100]  A. Hart,et al.  Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. , 1990, British Journal of Cancer.

[101]  U. Albert,et al.  Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy , 2014, Osteoporosis International.

[102]  T. Thomas,et al.  La vitamine D chez l'adulte : recommandations du GRIO , 2011 .

[103]  Sung-Bae Kim,et al.  Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01) , 2010, Breast Cancer Research and Treatment.

[104]  M. Tubiana,et al.  Cancer du sein et ostéoporose , 2009 .

[105]  G. Francini,et al.  Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. , 2007, Bone.

[106]  G. Hortobagyi,et al.  Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. , 1998, Cancer investigation.

[107]  T. Powles,et al.  Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.